Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

The treatments, which include medications like semaglutide, liraglutide and exenatide, have been linked to a slightly reduced dementia risk before, but this was based on observational studies ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that they really could protect against dementia ...

Ozempic is not marketed as a weight loss drug and is prescribed to those with type 2 diabetes to help manage their condition ...

The General Inspectorate of Health Activities (IGAS) has opened a clarification process regarding the marketing of the drug ...

Five GLP-1RAs are available in the UK-dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, which is the active ingredient in Ozempic and Wegovy. Ozempic is not marketed as a weight ...

Published and preliminary data have shown once-weekly exenatide to result in greater ... not meet noninferiority when compared with liraglutide. Semaglutide resulted in more patients reaching ...

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide ... pressure on Novo’s daily GLP-1 Victoza (liraglutide), although Ozempic is gaining traction ...